Advertisement

Topics

Trastuzumab Biosimilar Demonstrates Equivalence to Reference Product in HER2-Positive Breast Cancer

16:43 EDT 5 Jun 2018 | OncLive

The pathologic complete response rate associated with the trastuzumab biosimilar ABP 980 was equivalent to that of reference trastuzumab based on central laboratory evaluation in patients with HER2-positive early breast cancer enrolled in the phase III LILAC study.

Original Article: Trastuzumab Biosimilar Demonstrates Equivalence to Reference Product in HER2-Positive Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Trastuzumab Biosimilar Demonstrates Equivalence to Reference Product in HER2-Positive Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...